Developer docs
API playgroundTry for free, no card

Search company profiles

Adjuvatis

Full company profile

uuid000idgr

Namestring
Adjuvatis
Legal namestring
ADJUVATIS
Websiteurl
adjuvatis.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Adjuvatis SAS is a privately held French formulation services and product company headquartered at Bioparc Lyon (60 avenue Rockefeller, bâtiment Laënnec), founded in December 2013 to commercialize the i-Particles® technology originally developed in 2003 by a joint research unit between CNRS and bioMérieux. The company manufactures and supplies proprietary safe-by-design, surfactant-free, biodegradable poly-lactic-acid (PLA) nanoparticle delivery systems — i-Particles® (~200 nm) and the second-generation i-LipoP® (~230 nm, lipid-coated for nucleic acid vectorization including mRNA) — sold in plain, active-loaded and fluorescent/dyed variants, together with personalized formulation services (design, development, scale-up, characterization) and analytical services based on a Malvern Zetasizer Ultra Red platform.

The company serves pharmaceutical and biotech firms, vaccine developers, diagnostics companies and academic/research institutions, addressing challenges such as poor aqueous solubility of hydrophobic APIs, targeted and sustained delivery, vaccine immunogenicity enhancement, and the need for eco-compatible, biocompatible carriers. Commercial reach is delivered through direct B2B engagement for custom formulation projects and through specialty biotech distributors Tebubio and CliniSciences for catalog products; pipeline and applied research is supported by an extensive network of academic and institutional partners including CNRS, bioMérieux, INSERM, CEA, Université Lyon 1, IBCP, and European consortia such as ADITEC, DRIVE (H2020 ITN) and EuroNanoMed (FluNanoAir), with funding from BPI France, ANR and DGA.

Operationally, Adjuvatis is a micro-capability entity: a 1–10 employee team led by CEO Charlotte Primard, COO David Da Costa (PhD) and founders Bernard Verrier (PhD, Scientific Referent) and Bernard Mandrand (PhD, Senior Consultant), structured as an SAS with €50,000 share capital, no disclosed institutional investors, no disclosed revenue, and no funding rounds in the public record. The business model combines low-ticket catalog sales, quote-based custom formulation projects, and grant/consortium co-funding, which together suggest a research-services orientation rather than a scaled commercial product franchise at present.

Short descriptiontext

Adjuvatis is a Lyon-based French SAS (founded 2013) that develops and manufactures surfactant-free, biodegradable PLA-based nanoparticle drug delivery systems (i-Particles® and i-LipoP®) for pharmaceutical, biotech, vaccine and academic customers via catalog sales, custom formulation services and specialty distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulation, drug delivery systems, vaccine adjuvants, nanoparticle delivery, contract formulation services
Industry3 codes
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYIMAEAOAA
Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Delivery Systems
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales
TypeOne Time License
Description

Sale of i-Particles® and i-LipoP®-based products in various forms: plain, active-loaded, and fluorescent/dyed variants. Products available in different sizes and configurations for research purposes.

adjuvatis.com
2Custom Formulation Services
TypeProfessional Services
Description

Full-service API formulation offering from design through development, characterization, and customer support. Services include pharmaceutical data collection, loading prediction, feasibility studies, formulation optimization, medium/large scale production, and full study reports.

adjuvatis.com
3Analytical Services
TypeProfessional Services
Description

Characterization services for i-Particles® and i-LipoP® formulations using Malvern Zetasizer Ultra Red. Includes colloidal analysis, physico-chemical characterization, and in vitro/in vivo evaluation.

adjuvatis.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Product catalog - various configurations
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products offered in multiple configurations: plain i-Particles® (100-500nm), active-loaded particles (antibiotics, antioxidants, TLR/NOD ligands, peptides, antigens, enzymes), fluorescent/dyed variants (various fluorophores), and i-LipoP® (230nm, saline buffer).

adjuvatis.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adjuvatis formulates and manufactures proprietary safe-by-design drug delivery systems based on biodegradable PLA polymer nanoparticles, including its i-Particles® platform and the lipid-coated i-LipoP® variant for nucleic acid and mRNA delivery. The company sells catalog nanoparticle SKUs (plain, active-loaded, and fluorescent variants) and offers custom formulation development and analytical services to pharmaceutical, biotech, and research organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ≥79% encapsulation efficiency for certain APIs (e.g., panicein A hydroquinone)
+3 more records
Product overview1 text field

Adjuvatis offers a portfolio centered on two proprietary delivery platform technologies — i-Particles® (surfactant-free PLA-based polymer particles, average 200 nm) and i-LipoP® (i-Particles® core coated with a lipidic bilayer, ~230 nm, for nucleic acid vectorization) — sold as catalog products in plain, active, and fluorescent/dyed variants. The company complements its product catalog with a full personalized formulation service (design, development, characterization, support) and analytical services (Malvern Zetasizer-based colloidal and drug analysis, in vitro/in vivo evaluation). An i-LipoP® mRNA transfection kit is available through the distributor Tebubio.

Product and service1 record
1i-Particles®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1CNRS (French National Center for Scientific Research)
Strategic tierCoreTypeTechnology or Integration
Description

Origin of i-Particles® technology - developed in 2003 by joint research unit between CNRS and bioMérieux. Ongoing academic partnership for research and development.

adjuvatis.com
Strategic tierCoreTypeTechnology or Integration
Description

Co-developed i-Particles® technology in joint research unit with CNRS. bioMérieux is a global leader in in vitro diagnostics.

Strategic tierCoreTypeTechnology or Integration
Description

Academic partner providing research collaboration and access to scientific expertise in chemistry, biology, and pharmaceutical sciences.

4Lyon Biopole
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bioparc Lyon ecosystem partner providing access to biotech cluster, networking opportunities, and collaborative innovation events.

adjuvatis.com
Strategic tierCoreTypeTechnology or Integration
Description

Research partnership for drug delivery and formulation development. Located in Lyon, providing laboratory and research resources.

Strategic tierMajorTypeTechnology or Integration
Description

French Alternative Energies and Atomic Energy Commission. Research collaboration including ASIO project and FluNanoAir European project.

Strategic tierMajorTypeTechnology or Integration
Description

French National Institute of Health and Medical Research. Partnership in ASIO project and various research collaborations.

8DRIVE (European Innovative Training Network)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

H2020-funded ITN with 15 beneficiaries and 20+ partner organizations. Project: Driving next generation autophagy researchers towards translation (2017-2021).

adjuvatis.com
9FASTCURE Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

COVID-19 response consortium including Innophore, University of Graz, and acib. Focused on screening, identification and formulation of compounds to combat SARS-CoV-2.

adjuvatis.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Technology transfer office and innovation accelerator in Lyon ecosystem.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

German biotech company and ADITEC consortium partner. Joint development of recombinant influenza vaccine using Tetrahymena thermophila-derived haemagglutinin combined with i-Particles®.

Strategic tierMajorTypeTechnology or Integration
Description

Academic partner in ADITEC consortium for vaccine research. Department of Infectious Disease involved in influenza vaccine studies.

Strategic tierMajorTypeTechnology or Integration
Description

Italian academic partner in vaccine development research through ADITEC consortium.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborative research on solubilization of marine sponge compound (panicein A hydroquinone) for anti-cancer treatment against drug-resistant melanoma.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Official distributor for i-LipoP® mRNA transfection kit.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for i-Particles® and i-LipoP® product catalog.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novavax develops recombinant nanoparticle vaccines and Matrix-M adjuvant. It represents a large-scale vaccine company that Adjuvatis's i-Particles® adjuvant technology could partner with or compete against in the vaccine adjuvant market.

TypeBroad incumbent
Description

Evonik operates a major pharmaceutical CDMO business with specialty excipients, lipid excipients for RNA delivery (e.g., PhytoChol, lipids for LNPs), and formulation services. It competes with Adjuvatis in the pharmaceutical formulation and lipid-based delivery supply market.

TypeDirect peer
Description

Acuitas is a Vancouver-based specialist in lipid nanoparticle (LNP) delivery systems for mRNA therapeutics, including the LNP technology used in Pfizer-BioNTech's COVID-19 vaccine. It is a direct peer to Adjuvatis in the nucleic acid and mRNA delivery platform space, with both companies commercializing proprietary nanocarrier systems to pharma and biotech partners.

TypeDirect peer
Description

Precision NanoSystems (now part of Cytiva/Danaher) develops microfluidic-based manufacturing of lipid nanoparticles for nucleic acid delivery. Both companies sell nanoparticle delivery platforms and formulation services to pharma/biotech customers, making Precision Nanosystems a direct commercial peer to Adjuvatis.

TypeEmerging player
Description

Cilian is a German biotech developing recombinant vaccines using Tetrahymena thermophila expression systems, and is an active co-development partner of Adjuvatis (ADITEC consortium for recombinant influenza vaccine with i-Particles®). It represents an emerging player in vaccine development that depends on delivery platforms like Adjuvatis's.

TypeDirect peer
Description

Polymun Scientific is an Austrian CDMO specializing in liposomal formulation and GMP manufacturing of nucleic acid (mRNA, siRNA) drug products. Both companies are European formulation specialists offering custom development and analytical services to pharma/biotech customers.

TypeBroad incumbent
Description

CureVac is a clinical-stage mRNA therapeutics company developing prophylactic vaccines and molecular therapies. While it is much larger and integrated (its own pipeline rather than a delivery platform), it competes in the same end market (mRNA vaccines) that Adjuvatis's i-LipoP® technology is positioned to serve.

TypeDirect peer
Description

Arcturus develops LNP-enabled mRNA vaccines and therapeutics, including its STARR self-amplifying mRNA platform. The company is a direct competitor to Adjuvatis in LNP-based nucleic acid delivery, with overlapping pharma partnership and vaccine development ambitions.

TypeBroad incumbent
Description

Croda's Life Sciences division produces vaccine adjuvants (e.g., squalene emulsion systems) and specialty excipients for drug delivery. Its adjuvant portfolio is a broad incumbent option in the same vaccine-adjuvant and drug-delivery markets Adjuvatis serves.

TypeDirect peer
Description

Genevant is a lipid nanoparticle (LNP) delivery technology company developing RNA-based therapeutics. Its siRNA-LNP work with Alnylam/Roche and broader nucleic acid delivery platform directly overlaps with Adjuvatis's i-LipoP® offering for mRNA/dsRNA/DNA vectorization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adjuvatis

Pharmaceutical Drug Delivery Systemsadjuvatis.com

Adjuvatis is a Lyon-based French SAS (founded 2013) that develops and manufactures surfactant-free, biodegradable PLA-based nanoparticle drug delivery systems (i-Particles® and i-LipoP®) for pharmaceutical, biotech, vaccine and academic customers via catalog sales, custom formulation services and specialty distributors.

What Adjuvatis does

Adjuvatis SAS is a privately held French formulation services and product company headquartered at Bioparc Lyon (60 avenue Rockefeller, bâtiment Laënnec), founded in December 2013 to commercialize the i-Particles® technology originally developed in 2003 by a joint research unit between CNRS and bioMérieux. The company manufactures and supplies proprietary safe-by-design, surfactant-free, biodegradable poly-lactic-acid (PLA) nanoparticle delivery systems — i-Particles® (~200 nm) and the second-generation i-LipoP® (~230 nm, lipid-coated for nucleic acid vectorization including mRNA) — sold in plain, active-loaded and fluorescent/dyed variants, together with personalized formulation services (design, development, scale-up, characterization) and analytical services based on a Malvern Zetasizer Ultra Red platform.

The company serves pharmaceutical and biotech firms, vaccine developers, diagnostics companies and academic/research institutions, addressing challenges such as poor aqueous solubility of hydrophobic APIs, targeted and sustained delivery, vaccine immunogenicity enhancement, and the need for eco-compatible, biocompatible carriers. Commercial reach is delivered through direct B2B engagement for custom formulation projects and through specialty biotech distributors Tebubio and CliniSciences for catalog products; pipeline and applied research is supported by an extensive network of academic and institutional partners including CNRS, bioMérieux, INSERM, CEA, Université Lyon 1, IBCP, and European consortia such as ADITEC, DRIVE (H2020 ITN) and EuroNanoMed (FluNanoAir), with funding from BPI France, ANR and DGA.

Operationally, Adjuvatis is a micro-capability entity: a 1–10 employee team led by CEO Charlotte Primard, COO David Da Costa (PhD) and founders Bernard Verrier (PhD, Scientific Referent) and Bernard Mandrand (PhD, Senior Consultant), structured as an SAS with €50,000 share capital, no disclosed institutional investors, no disclosed revenue, and no funding rounds in the public record. The business model combines low-ticket catalog sales, quote-based custom formulation projects, and grant/consortium co-funding, which together suggest a research-services orientation rather than a scaled commercial product franchise at present.

Adjuvatis firmographics

Firmographics
Name
Adjuvatis
Legal name
ADJUVATIS
Website
https://adjuvatis.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Adjuvatis is a Lyon-based French SAS (founded 2013) that develops and manufactures surfactant-free, biodegradable PLA-based nanoparticle drug delivery systems (i-Particles® and i-LipoP®) for pharmaceutical, biotech, vaccine and academic customers via catalog sales, custom formulation services and specialty distributors.
Ownership category
akta.pro rank

Adjuvatis industry classification

Industry
Product category
Pharmaceutical Drug Delivery Systems
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYIMAEAOAA
Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT)

Keywords

  • Pharmaceutical formulation
  • Drug delivery systems
  • Vaccine adjuvants
  • Nanoparticle delivery
  • Contract formulation services

Where Adjuvatis is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Adjuvatis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales: Sale of i-Particles® and i-LipoP®-based products in various forms: plain, active-loaded, and fluorescent/dyed variants. Products available in different sizes and configurations for research purposes.
  2. Custom Formulation Services: Full-service API formulation offering from design through development, characterization, and customer support. Services include pharmaceutical data collection, loading prediction, feasibility studies, formulation optimization, medium/large scale production, and full study reports.
  3. Analytical Services: Characterization services for i-Particles® and i-LipoP® formulations using Malvern Zetasizer Ultra Red. Includes colloidal analysis, physico-chemical characterization, and in vitro/in vivo evaluation.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProduct catalog - various configurations

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Adjuvatis product offering

Product offering

Core offering

Adjuvatis formulates and manufactures proprietary safe-by-design drug delivery systems based on biodegradable PLA polymer nanoparticles, including its i-Particles® platform and the lipid-coated i-LipoP® variant for nucleic acid and mRNA delivery. The company sells catalog nanoparticle SKUs (plain, active-loaded, and fluorescent variants) and offers custom formulation development and analytical services to pharmaceutical, biotech, and research organizations.

Product overview

Adjuvatis offers a portfolio centered on two proprietary delivery platform technologies — i-Particles® (surfactant-free PLA-based polymer particles, average 200 nm) and i-LipoP® (i-Particles® core coated with a lipidic bilayer, ~230 nm, for nucleic acid vectorization) — sold as catalog products in plain, active, and fluorescent/dyed variants. The company complements its product catalog with a full personalized formulation service (design, development, characterization, support) and analytical services (Malvern Zetasizer-based colloidal and drug analysis, in vitro/in vivo evaluation). An i-LipoP® mRNA transfection kit is available through the distributor Tebubio.

Differentiator

Problem solved

Functional benefit

Products and services

  • i-Particles®

Quantifiable outcome

  • ≥79% encapsulation efficiency for certain APIs (e.g., panicein A hydroquinone)
  • +3 more outcomes

Companies that use Adjuvatis

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Adjuvatis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Adjuvatis partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core, major and minor.

  • CNRS (French National Center for Scientific Research)coreTechnology or IntegrationOrigin of i-Particles® technology - developed in 2003 by joint research unit between CNRS and bioMérieux. Ongoing academic partnership for research and development.
  • bioMérieuxcoreTechnology or IntegrationCo-developed i-Particles® technology in joint research unit with CNRS. bioMérieux is a global leader in in vitro diagnostics.
  • Université Lyon 1coreTechnology or IntegrationAcademic partner providing research collaboration and access to scientific expertise in chemistry, biology, and pharmaceutical sciences.
  • Lyon BiopolecoreStrategic or Co-development PartnerBioparc Lyon ecosystem partner providing access to biotech cluster, networking opportunities, and collaborative innovation events.
  • IBCP (Institute of Biology and Chemistry of Proteins)coreTechnology or IntegrationResearch partnership for drug delivery and formulation development. Located in Lyon, providing laboratory and research resources.
  • CEA (Commissariat à l'Énergie Atomique)majorTechnology or IntegrationFrench Alternative Energies and Atomic Energy Commission. Research collaboration including ASIO project and FluNanoAir European project.
  • INSERMmajorTechnology or IntegrationFrench National Institute of Health and Medical Research. Partnership in ASIO project and various research collaborations.
  • DRIVE (European Innovative Training Network)majorStrategic or Co-development PartnerH2020-funded ITN with 15 beneficiaries and 20+ partner organizations. Project: Driving next generation autophagy researchers towards translation (2017-2021).
  • FASTCURE ConsortiummajorStrategic or Co-development PartnerCOVID-19 response consortium including Innophore, University of Graz, and acib. Focused on screening, identification and formulation of compounds to combat SARS-CoV-2.
  • PULSALYSminorStrategic or Co-development PartnerTechnology transfer office and innovation accelerator in Lyon ecosystem.
  • Cilian AGmajorStrategic or Co-development PartnerGerman biotech company and ADITEC consortium partner. Joint development of recombinant influenza vaccine using Tetrahymena thermophila-derived haemagglutinin combined with i-Particles®.
  • Imperial College LondonmajorTechnology or IntegrationAcademic partner in ADITEC consortium for vaccine research. Department of Infectious Disease involved in influenza vaccine studies.
  • University of SienamajorTechnology or IntegrationItalian academic partner in vaccine development research through ADITEC consortium.
  • Université Côte d'Azur / CNRS / IPMCmajorStrategic or Co-development PartnerCollaborative research on solubilization of marine sponge compound (panicein A hydroquinone) for anti-cancer treatment against drug-resistant melanoma.
  • TebubiomajorChannel Partner/ Reseller/ DistributorOfficial distributor for i-LipoP® mRNA transfection kit.
  • CliniSciencesmajorChannel Partner/ Reseller/ DistributorDistributor for i-Particles® and i-LipoP® product catalog.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Adjuvatis competitors and assessment

Company assessment

Broad incumbents

  • Novavax: Novavax develops recombinant nanoparticle vaccines and Matrix-M adjuvant. It represents a large-scale vaccine company that Adjuvatis's i-Particles® adjuvant technology could partner with or compete against in the vaccine adjuvant market.
  • Evonik Industries: Evonik operates a major pharmaceutical CDMO business with specialty excipients, lipid excipients for RNA delivery (e.g., PhytoChol, lipids for LNPs), and formulation services. It competes with Adjuvatis in the pharmaceutical formulation and lipid-based delivery supply market.
  • CureVac: CureVac is a clinical-stage mRNA therapeutics company developing prophylactic vaccines and molecular therapies. While it is much larger and integrated (its own pipeline rather than a delivery platform), it competes in the same end market (mRNA vaccines) that Adjuvatis's i-LipoP® technology is positioned to serve.
  • Croda International: Croda's Life Sciences division produces vaccine adjuvants (e.g., squalene emulsion systems) and specialty excipients for drug delivery. Its adjuvant portfolio is a broad incumbent option in the same vaccine-adjuvant and drug-delivery markets Adjuvatis serves.

Direct peers

  • Acuitas Therapeutics: Acuitas is a Vancouver-based specialist in lipid nanoparticle (LNP) delivery systems for mRNA therapeutics, including the LNP technology used in Pfizer-BioNTech's COVID-19 vaccine. It is a direct peer to Adjuvatis in the nucleic acid and mRNA delivery platform space, with both companies commercializing proprietary nanocarrier systems to pharma and biotech partners.
  • Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva/Danaher) develops microfluidic-based manufacturing of lipid nanoparticles for nucleic acid delivery. Both companies sell nanoparticle delivery platforms and formulation services to pharma/biotech customers, making Precision Nanosystems a direct commercial peer to Adjuvatis.
  • Polymun Scientific: Polymun Scientific is an Austrian CDMO specializing in liposomal formulation and GMP manufacturing of nucleic acid (mRNA, siRNA) drug products. Both companies are European formulation specialists offering custom development and analytical services to pharma/biotech customers.
  • Arcturus Therapeutics: Arcturus develops LNP-enabled mRNA vaccines and therapeutics, including its STARR self-amplifying mRNA platform. The company is a direct competitor to Adjuvatis in LNP-based nucleic acid delivery, with overlapping pharma partnership and vaccine development ambitions.
  • Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery technology company developing RNA-based therapeutics. Its siRNA-LNP work with Alnylam/Roche and broader nucleic acid delivery platform directly overlaps with Adjuvatis's i-LipoP® offering for mRNA/dsRNA/DNA vectorization.

Emerging players

  • Cilian AG: Cilian is a German biotech developing recombinant vaccines using Tetrahymena thermophila expression systems, and is an active co-development partner of Adjuvatis (ADITEC consortium for recombinant influenza vaccine with i-Particles®). It represents an emerging player in vaccine development that depends on delivery platforms like Adjuvatis's.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Adjuvatis social profiles

Digital presence

Adjuvatis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adjuvatis leadership team

Management profile

Number of profiles

Profiles4 records

Adjuvatis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adjuvatis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adjuvatis

What does Adjuvatis do?

Adjuvatis formulates and manufactures proprietary safe-by-design drug delivery systems based on biodegradable PLA polymer nanoparticles, including its i-Particles® platform and the lipid-coated i-LipoP® variant for nucleic acid and mRNA delivery. The company sells catalog nanoparticle SKUs (plain, active-loaded, and fluorescent variants) and offers custom formulation development and analytical services to pharmaceutical, biotech, and research organizations.

Is Adjuvatis a public or private company?

Adjuvatis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Adjuvatis founded?

Adjuvatis was founded in 2013. It employs 1 to 10 people.

Where is Adjuvatis based?

Adjuvatis is headquartered in Lyon, France, in the Europe region.

How does Adjuvatis make money?

Three revenue lines are on record. Product Sales are the primary driver. The others are custom Formulation Services and analytical Services.

Who are Adjuvatis's main competitors?

Broad incumbents on record are Novavax, Evonik Industries, CureVac and Croda International. Direct peers are Acuitas Therapeutics, Precision NanoSystems (Cytiva), Polymun Scientific, Arcturus Therapeutics and Genevant Sciences. Cilian AG is listed as an emerging player.

Does Adjuvatis have an API?

No public API is recorded for Adjuvatis.

What industry is Adjuvatis in?

Adjuvatis's product category is Pharmaceutical Drug Delivery Systems. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales